Nontuberculous mycobacteria (NTM) are troublesome pathogens that can cause significant pulmonary disease in patients with cystic fibrosis (CF). Diagnosis can be difficult in the setting of underlying CF and treatment regimens are burdensome on both patients and providers. Recent consensus guidelines for treatment of NTM in CF have provided a guide for the CF community, however research is lagging regarding accuracy of our diagnostic abilities and treatment efficacy. In this review, we provide new insights into the complexity of NTM from emerging whole genome sequencing data, a summary of current NTM diagnosis and treatment guidelines, highlight new treatment options, and discuss future research projects which aim to better define which patients to treat and timing and duration of treatment. 
M. avium, Mycobacterium intracellulare, and Mycobacterium chimaera among others. 12, 13 The next most common are the Mycobacterium abscessus complex (MABSC), which include three subspecies, M.
abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M.
abscessus subsp. bolletii. MABSC are classified as "rapid growers,"
and are genetically quite distinct from MAC. 12, 13 Due to unknown mechanisms, CFTR dysfunction alone may predispose to patients to NTM infection since rates of CF-carrier status are high (30-50%) within the non-CF pulmonary NTM disease population. 19, 20 Among the NTM species, patients infected with MABSC are often younger, and may include children, with relatively more severe lung disease. 9, 21 MAC is more commonly seen in older, adult-diagnosed CF patients with a less severe phenotype, often due to presence of a residual function CFTR mutation. [21] [22] [23] There are, of course many exceptions to this observation, and CF patients of any age can develop NTM disease from either MAC or MABSC.
Of central concern within the CF community is identifying factors that place individuals at risk for infection. In CF (and non-CF) patients, the source(s) of NTM infection and modes of bacterial transmission are not clearly understood. NTM are generally thought to be acquired from the environment, as they reside in biofilms within plumbing and various water delivery systems, [24] [25] [26] [27] [28] as well as aquatic-type environments and soil. 29, 30 However, a limited number of studies have genetically linked environmental and patient isolates. [31] [32] [33] [34] Recently, studies of CF patient isolates from suspected outbreaks, suggest the potential for direct or indirect person-to-person transmission in CF clinics. 35, 36 In general, disease transmission studies require two types of data: genetic matching of paired isolates (patient vs environmental or patient vs patient) and epidemiological evidence of exposure and potential crossinfection. Genetic matching entails comparisons of DNA fingerprints generated via rep-PCR, pulsed field gel electrophoresis (PFGE) or whole genome sequencing (WGS). There are, however, no standardized thresholds of genetic relatedness by which two isolates are considered "the same" resulting in varied interpretations of the data.
Moreover, genetically matched isolates on their own are not enough to prove disease transmission as there must be also be convincing epidemiological evidence supporting cross-infection. 
| TREATMENT OF NTM PULMONARY DISEASE
In 2016, CFF/ECFS published consensus recommendations for the management of NTM in CF. 13 It important to note that data 1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography scan that shows multifocal bronchiectasis with multiple small nodules.
Appropriate exclusion of other diagnoses.
Microbiologic criteria (one of the following required):
1. Positive culture results from at least two separate expectorated sputum samples.
2. Positive culture result from at least one bronchial wash or lavage.
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM.
Adapted from Floto et al. 13 MARTINIANO ET AL. | 3 reviewed came from studies in patients without CF and to date there have been no randomized control trials of NTM treatment in the CF population. 52 Optimal treatment duration is unknown, but current recommendations are to achieve 12 consecutive months of negative cultures. 13 An example of a typical MAC and MABSC treatment schedule from the CFF/ECFS guidelines is shown in Figure 1 
FIGURE 1
Typical treatment schedules for individuals with CF with Mycobacterium abscessus or MAC pulmonary disease. (A) M. abscessus treatment is divided into an initial intensive phase with an oral macrolide (preferably azithromycin) and intravenous amikacin with one or more additional intravenous antibiotics (tigecycline, imipenem, cefoxitin) for 3-12 weeks (depending on severity of infection, response to treatment, and the tolerability of the regimen), followed by a continuation phase of oral macrolide (preferably azithromycin) and inhaled amikacin with 2-3 additional antibiotics (minocycline, clofazimine, moxifloxacin, linezolid). Antibiotic choices should be guided but not dictated by drug susceptibility testing. Baseline and interval testing for drug toxicity is essential (B). MAC treatment (for clarithromycin-sensitive disease) should be with a daily oral macrolide (preferably azithromycin), rifampin and ethambutol. An initial course of injectable amikacin or streptomycin should be considered in the presence of (i) AFB smear positive respiratory tract samples; (ii) radiological evidence of lung cavitation or severe infection; and (iii) systemic signs of illness. Baseline and interval testing for drug toxicity is essential (AFB, acid-fast bacilli; CF, cystic fibrosis; HRCT, high-resolution CT; MAC, Mycobacterium avium complex). Adapted from Thorax 2016;71:i1-i22.
Treatment of pulmonary disease due to MABSC is complicated because of the high level of in vitro resistance, need for intravenous antibiotics, high frequency of adverse reactions, and generally lower rates of successful treatment compared to MAC. MABSC culture conversion rates are typically reported in the 40-50% range.
14, [55] [56] [57] Among MABSC subspecies, M. abscessus susp. massiliense clearance rates are higher than M. abscessus subsp. abscessus. [58] [59] [60] In a study from France, a macrolide-based regimen resulted in 100% culture conversion in CF patients with M. abscessus susp. massiliense compared with 27% when infected with M. abscessus subsp. abscessus. 60 These differences are presumably related to the presence of a functional erm(41) gene in M. abscessus that results in inducible macrolide resistance, whereas in M. abscessus susp. massiliense the gene is nonfunctional and generally associated with susceptibility to macrolides. 58 The CFF/ECFS guidelines recommend that MABSC should be sub-speciated to assist in treatment decisions and prognosis. 13 MABSC treatment involves an intensive phase of therapy followed by a continuation phase. The intensive phase is used to rapidly reduce bacterial load and should include 3-12 weeks of intravenous amikacin plus one or more of the following agents:
intravenous tigecycline, imipenem, or cefoxitin, plus a macrolide (preferably azithromycin), plus one to two additional oral drugs. 13 Inclusion of a macrolide in the treatment of M. abscessus susp.
abscessus or M. abscessus susp. bolletii has been debated due to presence of an erm(41) gene in most strains and potential for inducible macrolide resistance 58 but still is included in the treatment plan outlined in the CFF/ECFS guidelines at this time. 13 The duration of the intensive phase is determined by severity of disease, response to therapy, and tolerability of the regimen. with MAC refractory to a macrolide-based three-drug regimen, 29%
achieved negative sputum cultures after addition of moxifloxacin. 63 Clofazimine has also been used with success as an alternative agent for patients. In a retrospective review, sputum conversion rates were 100% among 90 adult patients with MAC who were treated with clofazimine, ethambutol, and a macrolide. 65 In another study of 112 adult and pediatric patients, primarily with refractory disease and 20% of whom had CF, culture conversion was achieved in 42% of patients with MAC, 45% with MABSC, and 33% in patients with more than one NTM species. 66 In both studies, the drug was tolerated well with 6-14% of patients having to stop clofazimine because of drug-related intolerance.
Inhaled amikacin has been used for many years in patients intolerant to parenteral aminoglycosides or as an adjuvant to oral therapy, but adverse effects may limit its use. 67, 68 In a phase II randomized placebo-controlled multicenter trial examining the utility of inhaled liposomal amikacin when added to a standard three-drug regimen in patients with refractory MAC, approximately 32% of those assigned to amikacin achieved culture conversion to negative versus 9% in the placebo group. 69 In this study, 16% of patients receiving inhaled liposomal amikacin stopped the drug due to adverse events including: bronchiectasis exacerbation, dyspnea, other respiratory events with oropharyngeal pain, and allergic alveolitis, compared with none in the placebo group. A phase III trial of inhaled liposomal amikacin has completed enrollment and study results should be available soon. Linezolid is an oxalidinone with broad antimycobacterial activity that has been used to treat multidrug-resistant tuberculosis as well as NTM. However, the use of the drug has been limited by high rates of adverse reactions including peripheral neuropathy, optic neuritis, and cytopenias. 70, 71 Bedaquiline is a diarylquinoline approved for the treatment of multidrug-resistant tuberculosis in adults. The drug is an ATP synthase inhibitor with broad antimycobacterial activity with MICs for MAC ranging from 0.008 to .0.03 μg/mL. 72 Six non-CF patients with refractory MAC and four with MABSC were treated with bedaquiline as salvage therapy in addition to other antimycobacterial drugs. 73 On treatment, 90% had symptom improvement and there was evidence of microbiologic response with 50% of patients achieving at least one negative culture after 6 months.
Relapse following primary treatment of NTM is reported in up to 35% for MAC 74 and 23% for MABSC. 55, 57 Importantly, in patients with CF previously infected with NTM, the presence of a future, second NTM species is common, reported in up to 26% of patients at 5 years and 36% at 10 years following the first NTM species cultured. 14 With treatment, stabilization, or improvement in clinical symptoms of NTM pulmonary disease, including cough, sputum production, and fatigue, as well as radiographic measures have been shown. 57, 75 Longitudinal follow-up of cases of CF patients with NTM have also shown evidence of stabilization of pulmonary function decline. 14, 56 Despite guidelines, questions remain as to what is the most appropriate treatment regimen for NTM in CF patients, especially in the setting of co-infection. The CFF is supporting the Prospective Algorithm for the TrEatment of NTM in CF (PATIENCE) trial (NCT02419989) with the primary goal to develop an evidence-based treatment protocol to be used for first-time NTM treatment of CF patients. Additional objectives are to define an expected rate of response and tolerance to treatment using the current CFF/ECFS guidelines. Preliminary data from the Colorado CF center are promising 76 and there is planned expansion in early January 2018.
Establishing an expected rate of response to current therapies in the CF population is the first step toward assessing the impact of new therapies or testing alternative treatment strategies, including the potential for an early eradication approach or shortened antibiotic courses. Ideally, in the future we will have culture-independent identification of infection, as well as biomarkers of pathogen virulence or host susceptibility to disease to combine with standard clinical assessments to better guide who and when to treat, as well as duration of therapy.
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